Why the study?
Does low-molecular-weight heparin improve survival in patients with cancer diagnoses?
Does low-molecular-weight heparin improve survival in patients with cancer diagnoses?
This review suggests that low-molecular-weight heparins may offer survival advantages over unfractionated heparin in cancer patients, potentially due to antitumor effects beyond thromboembolism prevention.
No takes yet. Share an insight, caveat, or question.
May support LMWH preference in cancer; leaves open prospective RCT confirmation of survival benefit.
Cosgrove et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: